Search Results
10
Everything
Search Filters
Organization
Idorsia Pharmaceuticals Ltd
Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call
February 27, 2025 11:51 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day. Date:...
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations
February 26, 2025 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia’s outstanding convertible bond...
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
February 26, 2025 00:55 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Idorsia’s contribution to the development costs reduced by USD 100 millionViatris potential regulatory and sales milestones payments to Idorsia reduced by...
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
February 26, 2025 00:50 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed...
Bondholders approve amended terms of the 2025 convertible bonds
February 25, 2025 12:50 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR The proposed amendments to the terms of the 2025 convertible bond have been approved by the bondholders and will become binding and effective upon approval...
Idorsia publishes the resolutions for the upcoming bondholder meeting
February 12, 2025 17:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR The updated invitation to the bondholder meeting – scheduled for February 25, 2025 – sets out the terms of the resolutions to be voted uponUnaudited...
Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders
January 15, 2025 17:45 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand Allschwil, Switzerland – January 15,...
Idorsia publishes an invitation to a bondholder meeting
January 14, 2025 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on February 25, 2025, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on January...
Idorsia to call for a bondholder meeting
January 13, 2025 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 13, 2025Idorsia Ltd (SIX: IDIA) today announced that – in the coming days – the company intends to publish an invitation to...
Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan
December 20, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreementCompany in discussions with bondholders to restructure the company’s...